EXEL Earnings Prediction
The chart below shows how EXEL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EXEL sees a -0.78% change in stock price 10 days leading up to the earnings, and a +3.39% change 10 days following the report. On the earnings day itself, the stock moves by +0.32%. This data can give you a slight idea of what to expect for the next quarter's release.
EXEL Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
539.54M
14.33%
-15.32%
Gross Margin
96.79%
0.80%
-0.45%
Operating Margin
34.82%
1033.51%
-19.71%
Net Margin
21.87%
9840.91%
-38.38%
EPS
0.40
--
-48.05%
No Data Available
EXEL Earnings Analysis
Exelixis Inc Corporation (EXEL.O) Earnings Conference Call
Positive
Strong Q3 Revenue Performance: Excelixis delivered outstanding financial performance in Q3 2024 with total revenues of approximately $539.5 million, including cabozantinib franchise net product revenues of $478.1 million, up 9% quarter-over-quarter and 12% year-over-year.
Cabozantinib Revenue Surge: Cabozantinib franchise net product revenues reached $478 million, reflecting a strong demand and new patient starts contributing to revenue growth.
Cabozantinib Revenue Growth: Global cabozantinib franchise net product revenues generated by Excelixis and its partners grew to $653 million in Q3 2024, showcasing significant market expansion.
Strong Profitability Report: The company reported GAAP net income of approximately $118 million or $0.40 per share for Q3 2024, indicating strong profitability and effective cost management.
Share Buyback Commitment: Excelixis has committed $1 billion in share buybacks over the last two years, with an additional $500 million authorized to be completed by the end of 2025, reflecting confidence in the company's future growth.
Negative
Total Revenue Breakdown: The company reported total revenues of approximately $539.5 million, which included cabozantinib franchise net product revenues of $478.1 million.
Cabozantinib Franchise Performance: Gross tonnet for the cabozantinib franchise in the third quarter 2024 was 26%, which is lower than the gross tonnet we experienced in the second quarter 2024.
Gross Tonnet Deductions Decrease: This decrease in gross tonnet deductions in the third quarter 2024 is primarily related to lower Medicare Part D and DoD and TRICARE expenses.
Operating Expenses Comparison: Our total operating expenses, including restructuring and impairment charges for the third quarter of 2024 were approximately $352 million compared to $361 million in the second quarter of 2024.
GAAP Net Income Report: The company reported GAAP net income of approximately $118 million or $0.40 per share on a fully diluted basis for the third quarter 2024.
EXEL FAQs
How does EXEL typically perform around its earnings report dates?
Is Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EXEL Earning Call Sentiment
Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
EXEL.O
-2.39%Positive
The earnings call indicates strong financial performance with significant revenue growth, increased guidance, and a robust share repurchase program. The Q&A section reveals cautious optimism from analysts, with management emphasizing strategic collaborations and pipeline advancements. While there are risks related to economic factors and clinical trials, the overall sentiment is positive due to strong financial metrics, optimistic guidance, and shareholder returns, suggesting a likely stock price increase of 2% to 8% in the next two weeks.
